KBC Group NV Purchases 1,127 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

KBC Group NV grew its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 33.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,530 shares of the medical research company’s stock after purchasing an additional 1,127 shares during the quarter. KBC Group NV’s holdings in NeoGenomics were worth $67,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Arizona State Retirement System boosted its position in NeoGenomics by 2.0% during the second quarter. Arizona State Retirement System now owns 35,739 shares of the medical research company’s stock valued at $496,000 after buying an additional 708 shares during the period. Crossmark Global Holdings Inc. boosted its holdings in NeoGenomics by 2.9% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 29,494 shares of the medical research company’s stock valued at $409,000 after acquiring an additional 842 shares during the period. Fernwood Investment Management LLC grew its position in NeoGenomics by 1.0% during the 3rd quarter. Fernwood Investment Management LLC now owns 89,500 shares of the medical research company’s stock worth $1,320,000 after acquiring an additional 900 shares during the last quarter. Blue Trust Inc. grew its position in NeoGenomics by 42.3% during the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after acquiring an additional 987 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. increased its stake in NeoGenomics by 3.3% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 32,505 shares of the medical research company’s stock worth $451,000 after purchasing an additional 1,030 shares during the period. 98.50% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, General Counsel Alicia C. Olivo sold 5,175 shares of the business’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $15.36, for a total transaction of $79,488.00. Following the sale, the general counsel now owns 37,129 shares of the company’s stock, valued at $570,301.44. The trade was a 12.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Stephens reissued an “overweight” rating and set a $19.00 price objective on shares of NeoGenomics in a research note on Tuesday, July 30th. Needham & Company LLC reissued a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a research report on Wednesday, November 6th. Finally, Benchmark reissued a “buy” rating and issued a $18.00 price target on shares of NeoGenomics in a report on Tuesday, September 24th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, NeoGenomics currently has an average rating of “Buy” and a consensus target price of $20.25.

NeoGenomics Stock Performance

NASDAQ:NEO opened at $16.39 on Friday. The company has a quick ratio of 1.91, a current ratio of 1.99 and a debt-to-equity ratio of 0.37. The firm’s fifty day simple moving average is $14.63 and its 200 day simple moving average is $14.84. The stock has a market cap of $2.10 billion, a P/E ratio of -26.87 and a beta of 1.19. NeoGenomics, Inc. has a twelve month low of $12.77 and a twelve month high of $21.22.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, November 5th. The medical research company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The firm had revenue of $167.80 million for the quarter, compared to analyst estimates of $167.00 million. During the same quarter in the previous year, the firm posted ($0.06) EPS. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. As a group, research analysts predict that NeoGenomics, Inc. will post -0.17 EPS for the current year.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.